The former by platelet-neutrophil complexes 4 and the latter by release of proinflammatory mediators from thrombin-activated platelets. 5 Thereby, thrombin represents a central factor in both the pathogenesis of atherosclerosis and the occurrence of acute thrombotic events.
First, endogenous modulators of thrombin activity may indirectly contribute to the cardiovascular risk and the event rates. 6, 7 Therefore, given the critical importance of thrombin activity in cardiovascular disease, endogenous mechanisms controlling thrombin activity are of great importance. Second, it may be hypothesized that the extent of endogenous thrombin inhibition also affects the therapeutic efficiency of non-vitamin K-dependent oral anticoagulants. Two important endogenous thrombin inhibitors are known: antithrombin III activated by heparin and heparin cofactor II (HCII) activated by dermatan sulfate (DS). HCII is generally activated by chondroitin sulfate B (DS) and, in part, also by chondroitin sulfate, which are attached to the core proteins of a variety of proteoglycans such as versican and biglycan. Biglycan contains 2 N-terminal DS side chains and has indeed been shown to activate HCII. 8 It is to date unclear where biglycan is localized to fulfill its function to activate HCII and whether the localization is subject to regulation during atherosclerosis. Biglycan is in general synthesized by endothelial cells, SMCs, fibroblasts, and macrophages. [9] [10] [11] Accordingly, vascular biglycan deposition occurs in the neointima and the adventitia of arterial blood vessels. In line with a critical function of biglycan in the neointimal plaque matrix and hemostasis, biglycan was found to be absent from the luminal layer of thrombosederoded plaques. 12 Therefore, the absence of biglycan from the plaque surface might promote atherothrombosis. 12 In addition, endothelial cells express large amounts of biglycan and circulating biglycan has been detected in the plasma. Therefore, with respect to atherosclerosis, it is of interest whether biglycan is present in the glycocalyx and the subendothelial matrix and whether the amount of circulating biglycan is altered during atheroprogression. Furthermore, it is to date unknown whether biglycan as an endogenous thrombin inhibitor also ameliorates thrombin-driven inflammation during atheroprogression.
Another aspect of the biological function of biglycan is to contribute to the stability of the fibrous cap in accordance with the known function of biglycan in collagen fibrillogenesis. 13 However, the aforementioned potentially antiatherosclerotic functions of biglycan are opposed by published findings demonstrating that soluble biglycan promotes inflammation in acute highly inflammatory diseases such as sepsis and noninfectious renal injury 14, 15 and that it contributes to vascular lipid retention. 16, 17 All considered, the effect of biglycan on atherosclerosis in vivo and its underlying mechanisms can hardly be predicted because biglycan modulates both anti-and proatherosclerotic mechanisms. Therefore, the aim of this study was to determine the vascular compartmentalization of biglycan in a mouse model of atherosclerosis and to unravel the overall effect of biglycan on thrombin activity, inflammation, and atheroprogression using mice double-deficient in Apolipoprotein E and Bgn (ApoE −/− /Bgn −/0 mice). This study seems to be of translational interest because the extent of endogenous thrombin inhibition by biglycan/HCII may affect the response to pharmacological thrombin/Xa inhibitors and may contribute to the cardiovascular risk.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

General Characteristics of ApoE −/− /Bgn −/0 Mice
Basic characterization of ApoE −/− and ApoE −/− /Bgn −/0 mice detected no differences between genotypes with respect to heart rate, diastolic and systolic blood pressure, total body fat, and plasma concentrations of total cholesterol, low-density lipoprotein, very-low-density lipoprotein, high-density lipoprotein, and insulin ( Figure I in the online-only Data Supplement). In addition, physical activity, food intake, mean O 2 consumption, and mean CO 2 production were unchanged ( Figure II in the online-only Data Supplement).
Biglycan Circulates in Human and Murine Plasma and Localizes to the Wall of Small Blood Vessels in ApoE-Deficient Mice
DS (also called chondroitin sulfate B) is known to activate HCII, thereby inhibiting thrombin activity in a similar manner as the activated heparin-antithrombin III complex. Two DS side chains are attached to the N terminus of biglycan. In this study, it is considered that gagylated biglycan might serve as an inhibitor of thrombin activity in ApoE-deficient mice. In atherosclerosis, expression of biglycan has been demonstrated in atherosclerotic plaques 12, 18 where it may confer local inhibition of thrombin. Here, it was investigated whether biglycan (1) circulates, (2) is present in the glycocalyx, and (3) is deposited in the subendothelial matrix. In line with these assumptions, it was observed that biglycan circulates in human plasma and was even higher in the plasma of patients with acute coronary syndrome ( Figure 1A and 1B) when compared with patients without coronary heart disease. Importantly, patient groups did not differ with regard to basal clinical characteristics, risk factors and medication (Table I in the online-only Data Supplement). Similarly, biglycan was detectable in plasma of C57BL/6J wild-type controls and was increased in the plasma of atherosclerotic ApoE −/− mice ( Figure 1C and 1D). The vascular staining of biglycan showed a difference in biglycan localization between capillaries and arterioles. Capillaries were defined by isolectin B4-positive cells forming lumina ≤10 μm. Biglycan was clearly detectable on the luminal surface of capillary endothelial cells ( Figure 1E) Larger vessels such as arterioles and venules were defined by isolectin-or CD31-positive cells forming lumina ≥25 μm. In contrast to capillaries, biglycan was absent from the endothelial glycocalyx of arterioles ( Figure 1F ). However, arterioles were characterized by pronounced deposition of biglycan in the subendothelial matrix ( Figure 1F ). In arterioles of ApoE −/− / Bgn −/0 mice, biglycan was not detected ( Figure 1G ). Thus, a large biglycan-rich vascular compartment exists in ApoE −/− mice that may mediate luminal and subendothelial activation of HCII in addition to possible activation of HCII by soluble circulating biglycan. Therefore, the vascular biglycan-rich extracellular matrix of small vessels may counteract thrombin activation and may function as an endogenous mechanism to protect from exaggerated thrombin activation.
Activation of Thrombin and Platelets in ApoE −/− /Bgn −/0 Mice
Next it was tested, whether deletion of biglycan affected thrombin generation in ApoE −/− mice. Thrombin generation in plasma was determined with automated thrombography. As shown in Figure 2 , the endogenous thrombin potential (ETP) was increased in ApoE −/− /Bgn −/0 mice, a finding indicating increased thrombin activation in the absence of biglycan (Figure 2A-2C ). The kinetics of thrombin formation was not changed ( Figure 2D and 2E). The direct causality was shown by spiking the plasma of ApoE −/− /Bgn −/0 mice with DS causing reduced ETP. In contrast, spiking the plasma with biglycan core protein without DS side chains did not lead to reduction of increased ETP in ApoE −/− /Bgn −/0 mice. Furthermore, DS-induced ETP-reduction was blunted after digestion of DS with chondroitinase ABC, thereby underlining the importance of DS side chains for the biglycan-mediated activation of HCII ( Figure 2F ). Potential contamination of DS with heparins was excluded by digestion of DS with heparinase I/III showing no effect on DS-induced decrease in the ETP ( Figure 2G and 2H). Because the interaction between HCII and DS leads to thrombin inhibition, the level of HCII/thrombin complexes in plasma of ApoE-and ApoE/Bgn double-deficient mice was determined. Figure 2I shows that HCII/thrombin was indeed significantly decreased in ApoE/Bgn double-deficient mice.
Thrombin is an important activator of platelets. Therefore, intravital microscopy of platelet adhesion was performed in the uninjured A. carotis communis of either ApoE −/− or ApoE −/− /Bgn −/0 mice. Indeed, ApoE −/− platelets showed increased rolling on the endothelium of ApoE/Bgn double-deficient mice ( Figure 2J ). This effect was paralleled by increased surface expression of CD62P in thrombocytes, as determined by flow cytometric analysis, indicating increased platelet activation ( Figure 2K ).
To identify a possible prothrombotic phenotype in ApoE −/− / Bgn −/0 mice, occlusive thrombus formation in a photochemical model of arterial thrombosis with the photosensitizing dye Rose Bengal and tail bleeding time were analyzed. However, in both models, no hemostatic differences between ApoE −/− or To further corroborate the finding of increased macrophage presence in vascular lesions, the macrophage content of atherosclerotic lesions at the aortic root was determined by immunohistochemistry. During early atherosclerosis (in mice aged 15 weeks), macrophage content, as indicated by immunostaining of Mac-2 and F4/80, was strongly increased in ApoE −/− /Bgn −/0 mice ( Figure 3C -3F). In line with a proinflammatory macrophage-driven phenotype, the concentrations of circulating monocyte chemotactic protein-1, monocyte inflammatory protein-1α, interleukin (IL)-2, and IL-3 were higher in ApoE −/− /Bgn −/0 mice than in ApoE −/− mice. The concentrations of other cytokines, such as IL-4 and IL-6, showed strong trends toward downregulation. The concentration of tumor necrosis factor-α was unaffected. In addition, antiinflammatory IL-10 was upregulated possibly as a part of a counter regulatory adaptation ( Figure 3G ).
Increased Atherosclerosis in ApoE −/− /Bgn −/0 Mice
The extent of atherosclerosis was determined in mice aged 15 and 30 weeks. In line with enhanced thrombin generation and macrophage-driven inflammation, both the plaque burden in the aorta and the plaque size at the aortic root were significantly higher in 30-week-old ApoE −/− /Bgn −/0 mice ( Figure 4A -4D). To corroborate the conclusion of a proatherosclerotic effect of biglycan deficiency, mice double-deficient in Ldl receptor and Bgn (Ldlr −/− /Bgn −/0 ) were fed a Western-type diet and analyzed. These mice develop severe aortic aneurysms as previously shown by Tang et al. 19 Indeed, increased plaques at the aortic root ( Figure 4E ) and increased macrophage-driven inflammation were detected in these mice ( Figure 4F ). Thus, the key finding of increased atherosclerosis and increased macrophage-mediated inflammation in the absence of biglycan was confirmed in a second model of murine atherosclerosis.
Remodeling of Atherosclerotic Plaques in ApoE −/− /Bgn −/0 Mice
Alterations in the proteoglycan composition of the plaque matrix were sought in an unbiased approach through mass spectrometry in mice aged 15 weeks. As expected, biglycan was not detectable in aortas from ApoE −/− /Bgn −/0 mice. In addition, the expression of decorin, perlecan, and versican was unchanged ( Figure 5 ; complete proteomic data sets in Tables II and III in  the online-only Data Supplement) . Unexpectedly, the signal for the chondroitin sulfate proteoglycan aggrecan, which is typical of cartilage matrix, was increased. Furthermore, the expression of the proteoglycan prolargin was decreased. Immunostaining confirmed unaltered expression of decorin and versican and a trend toward increased expression of perlecan. In line with mass spectrometry, IHC staining of aggrecan detected an increase in aggrecan expression. The expression of prolargin was only slightly decreased in plaques at the aortic root ( Figure 5A-5C) .
Interestingly, increased numbers of α-smooth muscle actin-positive cells were detected in aortic root plaques from ApoE −/− /Bgn −/0 mice ( Figure 5D ). Whether these cells originate from vascular SMC, macrophages, or pericytes cannot be concluded from the present data. 20 There were no differences between the genotypes in 5-bromo-2′-deoxyuridine incorporation ( Figure 5E ). 
Pharmacological Thrombin Inhibition Alleviates Platelet Activation and Inflammation in ApoE −/− /Bgn −/0 Mice
The findings presented to date suggest that biglycan plays a role in balancing thrombin activity in ApoE-deficient mice and thereby moderates the progression of atherosclerosis in this model. This hypothesis was tested by treating ApoE −/− and Figure 6A ). Plaque size at the aortic root was significantly decreased in ApoE −/− /Bgn −/0 mice treated with argatroban when compared with the vehicle control group ( Figure 6B ). In addition, flow cytometric analysis of the aorta (Figure 6C and 6D) revealed a significant decrease in the numbers of aortic macrophages in response to argatroban. These results strongly suggest that increased thrombin activity was indeed the underlying cause of increased plaque inflammation and subsequent atherosclerosis in ApoE −/− /Bgn −/0 mice.
Discussion
This study found that genetic deletion of Bgn aggravates the development of atherosclerosis. The increase in plaque burden was seen in 2 models of atherosclerosis, ApoE −/− /Bgn −/0 mice and Ldlr −/− /Bgn −/0 double-deficient mice. Therefore, the current findings add important new information about the role of biglycan in atherosclerosis. To date, biglycan has been suspected of contributing to atheroprogression. The results of our studies showed that biglycan functions in atherosclerosis as a matrix-derived inhibitor of thrombin, thereby decreasing total thrombin activity and subsequent downstream events such as platelet activation and inflammation. This is based on the activation of HCII by the DS chains of biglycan 21, 22 and, in turn, inactivation of active thrombin. Importantly, biglycan-mediated thrombin inhibition does not mediate hemostatic effects because no effects on bleeding time and arterial thrombus formation were observed. From a translational perspective, biglycan may thereby affect cardiovascular risk and change the response to pharmacological interventions and may itself be a (pleiotropic) target of cardiovascular drugs. Specifically, it may be considered that patients with low biglycan-as reported for patients with low HCII expression-and therefore higher thrombin activity may be at a higher cardiovascular risk and that the response to non-vitamin K-dependent oral anticoagulants might be modulated by the level of endogenous thrombin inhibition. Currently, the use of non-vitamin K-dependent oral anticoagulants to treat acute coronary syndrome is being considered as an addition to single-or dual-antiplatelet therapy. 23, 24 Furthermore, biglycan content is regulated by statins, angiotensin type 1 receptor antagonists, and likely other drugs that are regularly used to treat patients at high risk of cardiovascular events. 18, 25, 26 No previous studies have addressed the question whether biglycan circulates in patients with coronary heart disease or in ApoE −/− mice. Interestingly, the current study found that circulating concentrations of biglycan are increased in ApoE −/− mice and in patients with acute coronary syndrome. Because biglycan content is also regulated by different external factors as described above, possible confounding influences in the analysis of human plasma samples by, eg, comorbidities and medication, cannot be completely ruled out. However, no obvious differences between the 3 patient groups were observed. The biological function of circulating biglycan in atherosclerosis has not yet been clarified, but in light of the current results, it may be interpreted as an antithrombotic counterregulation in the proatherosclerotic state. In addition, activated endothelial cells strongly express biglycan, 27 and it is shown here that biglycan-rich extracellular matrix is present as a part of the luminal glycocalyx of capillaries.
This may be of particular interest because it creates an enormous surface for 2-dimensional interactions of circulating HCII and DS-GAG chains of biglycan. This would be analogous to the interaction of antithrombin III and the heparan sulfate that also takes place in the endothelial glycocalyx 28 and adds a new mechanism for balancing hemostasis. In addition, it is shown here that biglycan is present in large amounts in the subendothelial space in arterioles. Therefore, endothelial cell-derived biglycan may provide a large compartment that facilitates biglycan/HCII interactions and could thereby inhibit thrombin activity and platelet function systemically. Circumstantial evidence from published studies points toward a local antithrombotic effect of vascular biglycan because the fibrous cap of thrombosed human eroded plaques is devoid of biglycan. 12 In human atherosclerosis, DS chains of biglycan are thought to be altered in a way that HCII activation is reduced. 8 Importantly, reduced HCII expression has been associated with aggravated atherosclerosis in humans. 29, 30 Mechanistically, this reduced expression of HCII may lead to increased thrombin-mediated activation of platelets, which in turn stimulate macrophage-mediated inflammation. 31, 32 As shown here, the absence of biglycan in ApoE −/− /Bgn −/0 mice causes increased thrombin activity and subsequently increased plaque inflammation. The extent of thrombin activation in ApoE −/− /Bgn −/0 mice did, however, not lead to changes in hemostasis or an overt thrombotic phenotype. However, because thrombosis models involve endothelial injury and denudation, this leads to collagen exposure and therefore strongly activates both platelets and the coagulation cascade. It is likely that such a strong activation of the hemostatic cascade will overwrite the lack of biglycan/HCII-mediated thrombin inhibition.
In line with a causal role of enhanced thrombin activity, it was demonstrated here that argatroban treatment reduced platelet activation and plaque inflammation in ApoE −/− /Bgn −/0 mice. In support of this hypothesis are findings indicating that activated platelets and increased platelet adhesion contribute to atheroprogression in the ApoE −/− model 33 and that HCII/ ApoE double-deficient mice develop increased atherosclerosis. 34 From a translational viewpoint, ApoE −/− /Bgn −/0 mice are a new model of systemic thrombin and platelet activation.
The current findings strongly suggest that increased thrombin activity and plaque inflammation caused by the absence of biglycan in the ApoE −/− knockout background account for the proatherosclerotic phenotype. A proinflammatory macrophage phenotype was evidenced by increased concentrations of circulating cytokines and increased numbers of macrophages in atherosclerotic lesions. In addition, it may be of importance that biglycan itself is an agonist of toll-like receptor-2 and toll-like receptor-4. 15 Therefore, the absence of this abundant toll-like receptor ligand may render macrophages hypersensitive to stimulation with other toll-like receptor ligands, such as hyaluronan. 35 Hyaluronan and the hyaluronan-binding proteoglycan versican are also abundant in atherosclerotic plaque 36 and were detected in atherosclerotic lesions in the present study.
Previous studies have shown that Bgn knockout mice exhibit a defect in bone formation and mineralization that is accompanied by inflammation and that cumulates in an osteoarthritic/osteoporotic phenotype. 37, 38 In our recent study, we found that the infusion of angiotensin-II into Ldlr/Bgn double-deficient mice causes severe abdominal aneurysms, a finding that again suggests that biglycan plays a protective role against maladaptive vessel remodelling. 19 Of note, the amount of lipid retention was unaffected although biglycan has been considered to be a lipoproteinbinding proteoglycan and to contribute thereby to the retention of lipoproteins. 39 Specifically, in vitro, in SMCs, it was shown that overexpression of biglycan increases low-density lipoprotein-binding. 40 This was confirmed by increased lipid retention in Ldlr −/− mice after overexpression of biglycan in SMCs. 41 Furthermore, it has been shown that biglycan contributes to the subendothelial accumulation of lipoprotein during early intimal thickening in humans because biglycan is expressed at sites of subsequent lipid deposition and macrophage accumulation. 16 These findings clearly indicated that biglycan can mediate low-density lipoprotein retention. However, the present study shows that genetic deletion of Bgn does not lead to reduced low-density lipoprotein-retention and atherosclerosis, likely because of the availability of sufficient negatively charged glycosaminoglycan chains from other proteoglycans. This conclusion was based on the present mass spectrometric and immunohistochemical analysis of vascular proteoglycans showing that the amounts of versican, perlecan, and decorin did not differ in ApoE −/− /Bgn −/0 mice. 16 Furthermore, upregulation of aggrecan was detected, which may contribute additional negatively charged glycosaminoglycan chains to compensate for the deletion of biglycan. Therefore, it is concluded that biglycan is not the limiting factor in intimal lipoprotein binding and that the other proteoglycans substitute for biglycan by offering sufficient binding sides for lipoproteins at least in advanced atherosclerosis. The conclusion that the absence of biglycan does not crucially affect lipoprotein retention in atherosclerotic plaques is also supported by the observation that chronic treatment with statins dramatically increases the concentrations of biglycan in atherosclerotic plaques without affecting the retention of lipoproteins in late atherosclerosis. 18 Comparing human atherosclerosis-prone internal carotid arteries with atherosclerosis-resistant internal thoracic arteries found no difference in biglycan content. 42 However, the current findings do not rule out the possibility that biglycan contributes to the subendothelial accumulation of lipoprotein during early intimal thickening in humans because biglycan is expressed at sites of subsequent lipid deposition and macrophage accumulation. 16 In conclusion, this study provides clear evidence that genetic deletion of Bgn is detrimental with respect to atherosclerosis in mice. Biglycan circulates and is present in the endothelial glycocalyx and subendothelial matrix and is identified as a relevant endogenous inhibitor of thrombin generation in murine atherosclerosis. Specifically, the deletion of Bgn increases thrombin activity and platelet activation without influencing hemostasis, but in turn contributes to increased inflammation of plaques and more rapid progression of atherosclerosis.
